Key result
Pharmacologic modulation of myocardial matrix metalloproteinases represents a potentially significant therapeutic target for preventing left ventricular remodeling in congestive heart failure.
Targeting matrix metalloproteinases and their tissue inhibitors offers a potential therapeutic strategy to mitigate adverse left ventricular remodeling in congestive heart failure.
No takes yet. Share an insight, caveat, or question.
MMP modulation remains a research target in HF remodeling; leaves open need for RCTs before any clinical consideration.
Rao et al. (1999) conducted a review in Congestive heart failure. Pharmacologic agents modulating myocardial matrix metalloproteinases was evaluated. Pharmacologic modulation of myocardial matrix metalloproteinases represents a potentially significant therapeutic target for preventing left ventricular remodeling in congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: